Ayala Pharmaceuticals (AYLA) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Ayala Pharmaceuticals (AYLAResearch Report) yesterday and set a price target of $23.00. The company’s shares closed last Monday at $12.64.

According to TipRanks.com, Olson is a 1-star analyst with an average return of -2.1% and a 43.2% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.

Ayala Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $17.75, implying a 44.5% upside from current levels. In a report issued on September 18, Raymond James also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.